BioCryst is profitable. Now it wants to buy more rare disease drugs

BioCryst, now a profitable rare disease biotech, is looking to expand its portfolio by acquiring additional rare disease drugs. The company is benefiting from new funding models and a growing ecosystem of smaller biotech buyers entering the rare disease space. Its success is being held up as a model for how smaller biotechs can thrive in this specialized market.

The Atomic take

BioCryst reaching profitability changes the math for rare disease dealmaking, showing that a smaller biotech can generate its own cash and then hunt for acquisitions rather than depending on a large pharma buyer to bankroll expansion. That matters because it opens a path for mid-tier players to consolidate orphan drugs that were previously too small to interest the giants. Watch which specific assets BioCryst targets and whether its new funding approach draws copycats among other newly profitable rare disease firms.

Related in Longevity